Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid Destabilization

ABSTRACT Human immunodeficiency virus type 1 (HIV-1) infection is dependent on the proper disassembly of the viral capsid, or “uncoating,” in target cells. The HIV-1 capsid consists of a conical multimeric complex of the viral capsid protein (CA) arranged in a hexagonal lattice. Mutations in CA that destabilize the viral capsid result in impaired infection owing to defects in reverse transcription in target cells. We describe here the mechanism of action of a small molecule HIV-1 inhibitor, PF-3450074 (PF74), which targets CA. PF74 acts at an early stage of HIV-1 infection and inhibits reverse transcription in target cells. We show that PF74 binds specifically to HIV-1 particles, and substitutions in CA that confer resistance to the compound prevent binding. A single point mutation in CA that stabilizes the HIV-1 core also conferred strong resistance to the virus without inhibiting compound binding. Treatment of HIV-1 particles or purified cores with PF74 destabilized the viral capsid in vitro. Furthermore, the compound induced the rapid dissolution of the HIV-1 capsid in target cells. PF74 antiviral activity was promoted by binding of the host protein cyclophilin A to the HIV-1 capsid, and PF74 and cyclosporine exhibited mutual antagonism. Our data suggest that PF74 triggers premature HIV-1 uncoating in target cells, thereby mimicking the activity of the retrovirus restriction factor TRIM5α. This study highlights uncoating as a step in the HIV-1 life cycle that is susceptible to small molecule intervention.

[1]  G. Towers,et al.  Cyclophilin A Renders Human Immunodeficiency Virus Type 1 Sensitive to Old World Monkey but Not Human TRIM5α Antiviral Activity , 2006, Journal of Virology.

[2]  P. Charneau,et al.  A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication , 1992, Journal of virology.

[3]  G. Gras,et al.  Macrophage activation and human immunodeficiency virus infection: HIV replication directs macrophages towards a pro-inflammatory phenotype while previous activation modulates macrophage susceptibility to infection and viral production. , 2006, Virology.

[4]  Joseph Sodroski,et al.  Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Wood,et al.  Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1 , 2010, Antimicrobial Agents and Chemotherapy.

[6]  Barbara Müller,et al.  A peptide inhibitor of HIV-1 assembly in vitro , 2005, Nature Structural &Molecular Biology.

[7]  J. Sodroski,et al.  Target Cell Type-Dependent Modulation of Human Immunodeficiency Virus Type 1 Capsid Disassembly by Cyclophilin A , 2009, Journal of Virology.

[8]  G. Towers,et al.  Use of a Transient Assay for Studying the Genetic Determinants of Fv1 Restriction , 2000, Journal of Virology.

[9]  J. Luban,et al.  Cyclophilin A and TRIM5α Independently Regulate Human Immunodeficiency Virus Type 1 Infectivity in Human Cells , 2006, Journal of Virology.

[10]  Wesley I. Sundquist,et al.  Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein , 2003, Journal of Virology.

[11]  D. Hazuda,et al.  Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor , 2009, Antimicrobial Agents and Chemotherapy.

[12]  Chun Tang,et al.  Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. , 2007, Journal of molecular biology.

[13]  G. Towers.  The control of viral infection by tripartite motif proteins and cyclophilin A , 2007, Retrovirology.

[14]  J. Luban,et al.  Cyclophilin A is required for TRIM5α-mediated resistance to HIV-1 in Old World monkey cells , 2005 .

[15]  R. Naviaux,et al.  The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses , 1996, Journal of virology.

[16]  C. Aiken,et al.  Cyclophilin A-Dependent Restriction of Human Immunodeficiency Virus Type 1 Capsid Mutants for Infection of Nondividing Cells , 2008, Journal of Virology.

[17]  C. Aiken,et al.  Evidence for a Functional Link between Uncoating of the Human Immunodeficiency Virus Type 1 Core and Nuclear Import of the Viral Preintegration Complex , 2006, Journal of Virology.

[18]  J. Kappes,et al.  Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.

[19]  J. Burns,et al.  Generation of high-titer pseudotyped retroviral vectors with very broad host range. , 1994, Methods in cell biology.

[20]  K. White,et al.  Design and Profiling of GS-9148, a Novel Nucleotide Analog Active against Nucleoside-Resistant Variants of Human Immunodeficiency Virus Type 1, and Its Orally Bioavailable Phosphonoamidate Prodrug, GS-9131 , 2007, Antimicrobial Agents and Chemotherapy.

[21]  T. Hope,et al.  HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Eric Barklis,et al.  Antiviral inhibition of the HIV-1 capsid protein. , 2003, Journal of molecular biology.

[23]  A. Debnath,et al.  A cell-penetrating helical peptide as a potential HIV-1 inhibitor. , 2008, Journal of molecular biology.

[24]  Mark Yeager,et al.  The structural biology of HIV assembly. , 2008, Current opinion in structural biology.

[25]  R. Wagner,et al.  Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. , 2000, Virology.

[26]  A. Engelman,et al.  Flexible use of nuclear import pathways by HIV-1. , 2010, Cell host & microbe.

[27]  C. Aiken,et al.  Association of Nef with the Human Immunodeficiency Virus Type 1 Core , 1999, Journal of Virology.

[28]  J. Luban.  Cyclophilin A, TRIM5, and Resistance to Human Immunodeficiency Virus Type 1 Infection , 2006, Journal of Virology.

[29]  M. Emerman,et al.  Evidence for Direct Involvement of the Capsid Protein in HIV Infection of Nondividing Cells , 2007, PLoS pathogens.

[30]  J. Nieman,et al.  HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention , 2010, PLoS pathogens.

[31]  E. Barklis,et al.  Virus Particle Core Defects Caused by Mutations in the Human Immunodeficiency Virus Capsid N-Terminal Domain , 2005, Journal of Virology.

[32]  C. M. Owens,et al.  The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys , 2004, Nature.

[33]  J. Sodroski,et al.  The Human TRIM5α Restriction Factor Mediates Accelerated Uncoating of the N-Tropic Murine Leukemia Virus Capsid , 2006, Journal of Virology.

[34]  C. Aiken,et al.  A Mutation in Alpha Helix 3 of CA Renders Human Immunodeficiency Virus Type 1 Cyclosporin A Resistant and Dependent: Rescue by a Second-Site Substitution in a Distal Region of CA , 2007, Journal of Virology.

[35]  W. Sundquist,et al.  Crucial for Viral Replication Virus Type 1 Core of Optimal Stability Is Formation of a Human Immunodeficiency , 2002 .

[36]  J. Sodroski,et al.  Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. , 2006, Virology.

[37]  C. Aiken.  Cell-free assays for HIV-1 uncoating. , 2009, Methods in molecular biology.

[38]  W. Blair,et al.  A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. , 2005, Antiviral research.

[39]  E. Freed,et al.  Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants That Exhibit Aberrant Core Morphology and Are Blocked in Initiation of Reverse Transcription in Infected Cells , 2001, Journal of Virology.

[40]  P. Bieniasz,et al.  Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors , 2003, Nature Medicine.